DZD8586 + rituximab + bendamustine

DZD8586 + rituximab + bendamustine is an investigational combination therapy composed of three agents: DZD8586, rituximab, and bendamustine. DZD8586 is a small molecule CDK9 inhibitor being developed for the treatment of hematological malignancies; it inhibits cyclin-dependent kinase 9, leading to suppression of transcription and ultimately decreased survival of malignant B cells. Rituximab is a chimeric monoclonal antibody that targets CD20 on B lymphocytes, resulting in cell lysis mainly through antibody-dependent cellular cytotoxicity and complement activation. Bendamustine is an alkylating agent, a chemotherapy drug that induces DNA crosslinking leading to cell death, and is primarily used to treat indolent non-Hodgkin lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. The combination is intended to provide synergy by targeting malignant B cells via multiple mechanisms: direct cytotoxicity, cell cycle/transcription blockade, and immune-mediated cell destruction.

Other names

DZD8586 + bendamustine hydrochloride + rituximab